Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (303)	2/20/2003 12:58:44 PM
From: Jibacoa	Respond to of 3722

PRCS Is up more than 13% and volume is more than 2x its daily average. Last week it announced that its Plenaxis treatment for advanced prostate Ca. gave good results in all patients (72) enrolled in an open-label trial.(The primary endpoint was to avoid surgical castration.<g>) Last week there was also an article on TSC recommending the stock after the news. The stock has been trading around 0.8 of book. Insiders hold around 10% and reportedly had done some buying, but the institutions that hold more than 75% of the float have done some selling.<g> The shares have been trading below the reported cash/share.($3.80) siliconinvestor.com The stock needs to close above its August 30 H of 3.93 before it can test its more heavier resistance (from April 2002) at the 5.85 to 6 level, but R/R at this level appears favorable.<g> siliconinvestor.com Bernard